An extraordinary @Nature paper has just landed from the lab of @Sergiu_P_Pasca at @Stanford - led by Konstantin Kaganovsky. They have found a way to create "xenocortical mice" which have ~92% of their cortex occupied by a cortical organoid derived from human stem cells. This human-derived cortical graft integrates deeply with the host nervous system, supporting organised neural activity and behaviour.
This study is a milestone in synthetic biology and chimera research. It has the potential to generate multiple medical breakthroughs by providing an enhanced biological model of human brain tissue that allows behavioural as well as neural and genetic assays.
The Stanford team have been exceptionally thorough and proactive in addressing ethical concerns that comes from this frontier work. But their pioneering work nonetheless raises many open questions: are the xenocortical mice conscious? Do they have any human-like properties of consciousness or cognition?
@NitaFarahany and I will be addressing some of these questions in a forthcoming commentary - where we'll also offer an ethically-informed roadmap to guide this important research as it progresses. In this context, "pacing the frontier" really does make sense 😉
Read the Stanford @nature paper here, and buckle up. It's wild. nature.com/articles/s41586-0…
In partnership with metapsy.org, we built an interactive dashboard for exploring the data. Users can:
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports
Dashboard: metapsy.org/sypres/mdma-ptsd
Our database includes 60+ effect sizes, encompassing all PTSD outcomes and timepoints reported by arm in each of the 6 RCTs included. This database can be downloaded from our website (sypres.io) or imported directly into R using the metapsyData package.
Here, MDMA showed a greater reduction in PTSD symptoms compared to control conditions, with a pooled Hedges’ g = -0.71. But important caveats: small studies, functional unblinding challenges, and a low certainty rating with the GRADE approach should contextualize our results.
This is the second installation in our sypres.io initiative featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data
Psychedelic science has experienced the benefits and drawbacks of hype. However, new results are rarely contextualized in the historical body of evidence in an accessible manner. We need more robust, living evidence synthesis that is visible and accessible to all stakeholders.
In partnership with metapsy.org we built an interactive dashboard for exploring the data. Users can:
• Filter studies by characteristics
• Test different analysis parameters
• Test moderators
• Download figures and reports
Dashboard: metapsy.org/sypres/psilocybi…
Our database includes 200+ effect sizes, encompassing all depression outcomes and timepoints reported by arm in each of the 15 RCTs included. This database can be downloaded from our website (sypres.io) or imported directly into R using the metapsyData package.
Here, psilocybin showed a greater reduction in depression scores compared to control conditions, with a pooled Hedges’ g = -0.90. But important caveats—small studies, blinding challenges, risk of bias, and design heterogeneity, which we discuss in the paper.
sypres.io is our new initiative featuring:
📊 Regularly updated meta-analyses
🔍 User-guided sensitivity and moderation analysis
🕵️ Transparent study quality & risk-of-bias assessments
⚙️ Open code & data












